NCT00125190View on ClinicalTrials.gov

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Insulin-Like Growth Factor-1 DeficiencyGrowth Disorders
Interventions
DRUG

rhIGF-1 (mecasermin) for a period of 86 weeks

Once a day rhIGF-1 injections

Trial Locations (1)

94005

Ipsen, Brisbane

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY